Making up for scrapped IPO, melanoma diagnostics company DermTech raising $20M
DermTech has a biopsy-free approach to test for melanoma - using an adhesive patch to collect skin cells and test if the RNA expression is consistent with cancer.
After withdrawing IPO, DermTech raises $2.4M for its RNA-based, biopsy-free melanoma diagnostic
San Diego skin cancer diagnostics startup DermTech is developing gene classifiers and expression tests to help more accurately screen for dermatologic issues. It just raised $2.4 million to do so, according to a regulatory filing – an interesting funding notice, given its announcement last year that it was readying for – and then withdrawing – a $25 […]
presented by
Market Trends to Watch for Health Systems and Their Specialty Pharmacies
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.